MYC and cancer: Studies have found that in drug-resistant ovarian cancer (25), PKM2 can bind to the c-Myc promoter region to determine the metabolic direction of pyruvate, thereby up-regulating glycolysis and promoting the proliferation and drug resistance of cancer cells.